Eisai Co Ltd stock (JP3160400002): Jefferies trims price target as Tokyo shares hover near 4,000 yen

Eisai Co Ltd shares on the Tokyo Stock Exchange traded close to 4,000 yen on 05/29/2026 as Jefferies recently lowered its price target on the Japanese pharma group from 5,000 yen to 4,000 yen while maintaining a Hold stance, highlighting a more cautious valuation backdrop.

Eisai Co Ltd shares were changing hands near the 4,000 yen mark on the Tokyo Stock Exchange on 05/29/2026 after Jefferies recently revised its valuation framework for the Japanese pharmaceutical company, trimming its price target from 5,000 yen to 4,000 yen and reiterating a Hold rating, according to a report cited by MarketScreener as of 05/28/2026.

The stock last closed at 4,043 yen in Tokyo, placing it close to the new Jefferies target and implying only limited upside against that benchmark view, based on data compiled by MarketScreener as of 05/28/2026.

As of: 05/29/2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Eisai
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Tokyo, Japan
• Core markets: Japan, United States, Europe, Asia
• Key revenue drivers: Prescription drugs for neurology and oncology, including dementia and cancer therapies
• Home exchange/listing venue: Tokyo Stock Exchange (4523)
• Trading currency: JPY

The stock traded at 4,043 yen on 05/28/2026 on the Tokyo Stock Exchange, according to MarketScreener as of 05/28/2026.

Eisai Co Ltd: core business model

Eisai focuses on researching and commercializing branded therapies in neurology and oncology, with sales concentrated in Japan and major overseas markets such as the United States and Europe.

Valuation metrics and multiples for Eisai Co Ltd

MarketScreener data as of 05/28/2026 indicate that analysts following Eisai see an average price target of about 4,888 yen per share, modestly above the latest close near 4,043 yen, suggesting the stock trades at a discount to the broader sell-side consensus despite the more cautious stance from Jefferies.

Within that framework, Jefferies recently decreased its target to 4,000 yen from 5,000 yen while keeping a Hold rating, pointing to a more measured risk-reward profile even as other analysts collectively expect higher levels over the medium term, according to a summary cited by MarketScreener and Moomoo as of late May 2026.

Conclusion

With Eisai Co Ltd shares trading close to 4,000 yen and Jefferies lowering its target price to that level while maintaining a Hold view, the stock is currently valued near one influential banks fair-value estimate.

At the same time, the average analyst target around 4,888 yen per MarketScreener suggests some remaining upside versus consensus expectations, underscoring a valuation picture that balances near-term caution against longer-term growth assumptions in neurology and oncology therapies.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.